Stock ALCOX NICOX SA
Add to a list
To use this feature you must be a member
Log inSign up

Nicox SA Share Price

Equities

ALCOX

FR0013018124

Pharmaceuticals

Real-time Euronext Paris
Other stock markets
 10:53:46 21/01/2025 GMT 		5-day change 1st Jan Change
0.3050 EUR +1.33% Intraday chart for Nicox SA -0.97% +8.54%
12-04 Nicox: commercial launch of Zerviate eye drops in China CF
12-04 France's Nicox Logs First Commercial Sale for Zerviate Eye Drop in China MT

Valuation: Nicox SA

Capitalization 20.78M 21.61M 19.62M 17.57M 30.94M 1.86B 34.51M 238M 88.33M 769M 81.05M 79.38M 3.36B P/E ratio 2023
-1.05x
P/E ratio 2024 * -1.25x
Enterprise value 30.02M 31.22M 28.34M 25.38M 44.7M 2.69B 49.85M 344M 128M 1.11B 117M 115M 4.86B EV / Sales 2023
7.54x
EV / Sales 2024 * 3.3x
Free-Float
95.66%
Yield 2023 *
-
Yield 2024 * -
More valuation ratios * Estimated data

Chart: Nicox SA

Dynamic Chart

Latest news: Nicox SA

Nicox: commercial launch of Zerviate eye drops in China 12-04 CF
France's Nicox Logs First Commercial Sale for Zerviate Eye Drop in China 12-04 MT
Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2024 17/10/24 CI
France's Nicox Signs Vyzulta Royalty, Equity Financing Deal with Soleus Capital 14/10/24 MT
Nicox: financing agreement with Soleus 14/10/24 CF
Nicox Enters Exclusive Research, Licensing Deal for Eye Disease Drug 23/09/24 MT
Nicox: research agreement with Glaukos Corporation 23/09/24 CF
Nicox Partner Secures Approval to Commercialize Eye Drop in China 18/09/24 MT
Nicox: partner receives approval in China 18/09/24 CF
Certain Ordinary Shares of Nicox S.A. are subject to a Lock-Up Agreement Ending on 12-SEP-2024. 11/09/24 CI
Nicox: former CEO steps down from the Board of Directors 04/09/24 CF
Nicox SA Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 25/07/24 CI
Nicox appoints new Chairman of the Board of Directors 16/07/24 CF
More news

Press Releases: Nicox SA

Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights 06:30am GL
Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream 12-04 GL
Nicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected 12-03 AQ
Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected 12-02 GL
Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial 11-19 GL
More press releases

News in other languages: Nicox SA

Trump envoie ses premiers scuds 08:02am
En direct des marchés : ça bouge chez Renault et Eramet, fiançailles pour Generali et Natixis, Orsted souffre 07:53am
Nicox : Point d’activité et résumé financier du quatrième trimestre 2024 06:30am
Nicox : Lettre aux Actionnaires 12-18
Nicox : lancement commercial du collyre Zerviate en Chine 12-04
More news

Quotes and Performance

1 day+1.33%
1 week-0.97%
Current month+8.54%
1 month+5.17%
3 months+13.38%
6 months+76.30%
Current year+8.54%
More quotes

Course Extremes

1 week
0.29
Extreme 0.293
0.31
1 month
0.28
Extreme 0.28
0.34
Current year
0.28
Extreme 0.281
0.34
1 year
0.14
Extreme 0.14
0.49
3 years
0.14
Extreme 0.14
2.66
5 years
0.14
Extreme 0.14
6.27
10 years
0.14
Extreme 0.14
13.68
More quotes

Managers and Directors: Nicox SA

Director TitleAgeSince
Gavin M. Spencer CEO
 Chief Executive Officer 54 27/02/2024
Sandrine Gestin DFI
 Director of Finance/CFO 57 31/12/2014
Doug Hubatsch CTO
 Chief Tech/Sci/R&D Officer - 12/12/2021
Manager TitleAgeSince
Gavin M. Spencer BRD
 Director/Board Member 54 07/04/2024
Damian Marron CHM
 Chairman 63 15/07/2024
Christine Placet BRD
 Director/Board Member - 03/09/2024
More insiders

Specialty & Advanced Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
NICOX SA Stock Nicox SA
+1.33%-0.97%-27.73%-88.38%21.61M
MERCK KGAA Stock Merck KGaA
+0.40%+1.17%-3.68%-26.38%64.2B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
-0.44%-1.97%-3.36%-21.67%7.5B
HALOZYME THERAPEUTICS, INC. Stock Halozyme Therapeutics, Inc.
-1.03%+1.22%+60.47%+63.29%6.97B
YUHAN CORPORATION Stock Yuhan Corporation
-2.09%-4.72%+119.77%+142.29%6.83B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-0.91%-5.64%+22.69%+26.40%5.92B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-0.09%+6.60%+27.83%-21.43%3.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+2.09%+5.21%+30.66%+21.96%2.15B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
-0.34%+0.45%+36.39%+29.16%2.08B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+2.19%-0.18%-35.41%+13.84%1.71B
Average +0.11%+0.82%+22.76%+13.91% 10.06B
Weighted average by Cap. +0.03%+0.96%+12.74%-2.24%
See all sector performances

Financials

2023 2024 *
Net sales 4.03M 4.19M 3.81M 3.41M 6.01M 362M 6.7M 46.26M 17.14M 149M 15.73M 15.41M 653M 6.3M 6.55M 5.95M 5.33M 9.38M 565M 10.46M 72.26M 26.78M 233M 24.57M 24.07M 1.02B
Net income -14.97M -15.56M -14.13M -12.65M -22.29M -1.34B -24.85M -172M -63.61M -554M -58.37M -57.17M -2.42B -14.2M -14.77M -13.41M -12.01M -21.14M -1.27B -23.58M -163M -60.36M -525M -55.39M -54.24M -2.3B
Net Debt 9.24M 9.61M 8.72M 7.81M 13.76M 828M 15.34M 106M 39.28M 342M 36.04M 35.3M 1.5B -
More financial data * Estimated data

Company Profile

Logo Nicox SA
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.
Employees
28
Sector
Pharmaceuticals
More about the company

Quotes

Date Price Change Volume
21/01/25 0.3050 € +1.33% 22,010
20/01/25 0.3010 € -0.33% 49,216
17/01/25 0.3020 € 0.00% 101,343
16/01/25 0.3020 € -0.82% 131,759
15/01/25 0.3045 € -1.14% 65,627

Real-time Euronext Paris, January 21, 2025 at 10:53 am

More quotes

Income Statement and Estimates

income-statement-evolution-chart NICOX-SA More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
surperformance-ratings-light-chart NICOX-SAMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3010EUR
Average target price
1.000EUR
Spread / Average Target
+232.23%
Consensus
Profit revisions
estimates-change-chart NICOX-SA Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart NICOX-SA Company calendar
  1. Stock Market
  2. Equities
  3. ALCOX Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition